Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace You Might Also Like Meet the Scientist Who Admits His MS Therapy is 'Largely Ineffective.' November 28, 2017 AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication October 18, 2017 The Verdict Is In: ConMed???s SurgiQuest Liable for $2.2 Million in Compensatory Damages April 11, 2017
The Verdict Is In: ConMed???s SurgiQuest Liable for $2.2 Million in Compensatory Damages April 11, 2017
